We Can Medicines Past Earnings Performance
Past criteria checks 1/6
We Can Medicines's earnings have been declining at an average annual rate of -20%, while the Consumer Retailing industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 5.4% per year. We Can Medicines's return on equity is 1.8%, and it has net margins of 0.5%.
Key information
-20.0%
Earnings growth rate
-24.2%
EPS growth rate
| Consumer Retailing Industry Growth | 0.05% |
| Revenue growth rate | 5.4% |
| Return on equity | 1.8% |
| Net Margin | 0.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How We Can Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,123 | 15 | 990 | 0 |
| 30 Sep 23 | 3,112 | 15 | 998 | 0 |
| 30 Jun 23 | 3,114 | 23 | 1,004 | 0 |
| 31 Mar 23 | 3,208 | 62 | 997 | 0 |
| 31 Dec 22 | 3,303 | 100 | 994 | 0 |
| 30 Sep 22 | 3,206 | 95 | 962 | 0 |
| 30 Jun 22 | 3,134 | 92 | 941 | 0 |
| 31 Mar 22 | 2,964 | 65 | 914 | 0 |
| 31 Dec 21 | 2,794 | 39 | 886 | 0 |
| 31 Dec 20 | 2,667 | 43 | 834 | 0 |
Quality Earnings: 6929 has high quality earnings.
Growing Profit Margin: 6929's current net profit margins (0.5%) are lower than last year (3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 6929's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: 6929's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6929 had negative earnings growth (-85.2%) over the past year, making it difficult to compare to the Consumer Retailing industry average (-8.7%).
Return on Equity
High ROE: 6929's Return on Equity (1.8%) is considered low.